Efficacy and Safety of Uronext® in Women With Cystitis

NCT05945667 | Completed

• 1 other identifier: UN-1
• Study Type: interventional
• Target: 111
• Locations: 1 country
• Sites: 1

Brief Summary

The study is designed as a prospective parallel open label, two-arm, single center study exploring efficacy and safety of the use of the dietary supplement Uronext in women with cystitis in the acute stage. 120 otherwise healthy women with acute cystitis infection confirmed with the urine bacteriological examinations, aged 18-18 years, will be recruited. The distribution of patients will be done in 1:1 ratio. Control group will receive standard therapy, Monural (fosfomycin trometamol) 3 g, at the first day of the trial. The second group will also receive Monural (fosfomycin trometamol) 3 g, at the first day of the trial as well as Uronext food supplement, 1 time per day for the first 7 days. After the 7 day break, participants in the second group will follow supplementation scheme for the next 3 month. Primary objective of the study is evaluation of the effectiveness of the dietary supplement Uronext in women with cystitis in the acute stage in the prevention of subsequent exacerbations of recurrent cystitis during 3 months of observation, measured as the number of relapses throughout the study period. Participnats will also fill in urination diary and questionnaires related to pain perception, quality of life and cystitis symptoms. Urine samples will be further examined at the follow up visits. Safety will be evaluated based on reported adverse events, assessment of vital signs and laboratory evaluation.

Conditions

Cystitis

Outcome Measures

Primary Outcomes (1)

• Cystitis relapses

  Proportion of patients who did not have relapses of the disease at Visit 3

  3 months

Secondary Outcomes (12)

• Pain intensity on the 100 mm Visual Analog Scale

  3 days

• Urinary urge severity on the 100 mm Visual Analog Scale

  6, 24, 48, and 72 hours

• Urinary frequency severity on the 100 mm Visual Analog Scale

  6, 24, 48, and 72 hours

• Recurrence rate

  3 months

• Urination frequency

  3 days

Study Arms (2)

Monural

ACTIVE COMPARATOR

3000 mg of fosfomycin trometamol per sachet

Drug: Monural

UroNext + Monural

EXPERIMENTAL

3000 mg of fosfomycin trometamol per sachet 500 mg of Qcran, 2000 mg of D-mannose, 5 mcg of vitamin D3 per sachet

Drug: Monural; Dietary Supplement: UroNext

Interventions

Monural DRUG

1 sachet, only 1st day of trial

Monural; UroNext + Monural

UroNext DIETARY_SUPPLEMENT

1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months

UroNext + Monural

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Women between the ages of 18 and 80.
• Patients who are able to fill out questionnaires, and wish to take part in the study.
• Cystitis in the acute stage.
• Informed consent to participate in the study.
• The patient's willingness and ability to fulfill the requirements of the protocol throughout the study.
• Consent of the patient and partner with preserved reproductive potential to use adequate methods of contraception (for example, a double barrier method) during the entire period of the study (including the period of follow-up).
• The presence of the gynecologist's conclusion obtained within 6 months before the patient's participation in the study about the absence of concomitant pathologies that can distort the results of the study.
• The presence of the results of bacteriological urine tests obtained within 7-10 days before the patient's participation in the study, pathogens of infections of the lower urinary tract. If the results of urine bacteriological examinations are not available, the results of urine culture tests performed at Visit 1 will be taken into account.

You may not qualify if:

• Patients with signs of upper urinary tract infection, such as temperature above 38°C, side/lower back pain, or soreness.
• Burdened allergic history.
• Hypersensitivity to any of the components that make up the investigational drugs.
• Patients with congenital anomalies in the development of genitourinary organs (exstrophy of the bladder, hypospadias, epispadias).
• Patients after undergoing surgical interventions on the organs of the genitourinary system.
• Any malignant neoplasm in the anamnesis.
• Unsatisfactory glycemic control (HbA1c ≥8%) in diabetes mellitus.
• Patients with uncontrolled infection as a result of exposure to human immunodeficiency virus (HIV) and/or active hepatitis.
• Patients with a history of drug or alcohol dependence within the last 5 years.
• Any clinically significant condition due to which, according to the researcher, the patient cannot take part in the study;
• Pregnancy, lactation, pregnancy planning during the study.
• Patients with any other serious or uncontrollable physical or mental condition/disease that the Researcher determines may put the patient at high risk of being removed from the study may disrupt or disprove the results of the study or likely prevent the patient from complying with the requirements of the study or completing the study.
• Participation in another clinical trial less than 6 months before the start of the study.
• Any other conditions that the researcher believes may indicate that the patient is not eligible to participate in the study.

Sponsors & Collaborators

• PharmaLinea Ltd.: lead
• NPO Petrovax Pharm LLC.: collaborator

Study Sites (1)

Urology Clinic of Moscow State University of Medicine and Dentistry

Moscow, Russia

Location

MeSH Terms

Conditions

Cystitis

Condition Hierarchy (Ancestors)

Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2023
• First Posted: July 14, 2023
• Study Start: June 7, 2021
• Primary Completion: December 21, 2021
• Study Completion: February 28, 2022
• Last Updated: July 27, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

RU (1)